As discussed previously, as the primary pathophysiological defect in DMD is the marked susceptibility to contraction-induced membrane stress, a unique therapeutic approach is the use of synthetic membrane stabilizers to prevent muscle damage by directly stabilizing the dystrophin-deficient muscle membrane (Houang et al., 2015; 2017). This evidence concerns the gene DMD and Duchenne muscular dystrophy.